# US 2021/0267960 A1 · Methods of treatment of inflammatory cytokine-related arthritic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267960 A1
- Document ID: US20210267960A1
- Status: Published application
- Kind: A1
- Application number: 17/185,034
- Filed: 2021-02-25
- Published: 2021-09-02
- Earliest claimed: 2020-02-28
- Applicants: Bridge Pharma Inc.
- Inventors: A.K. Gunnar Aberg; Vincent B. Ciofalo; Kresimir Pucaj
- Web page: https://patentgrep.com/patent/US20210267960A1

## CPC

- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating a patient suffering from a TNFα associated arthritic disorder with the cytokine release inhibitor norketotifen include orally or topically administering to the subject in need thereof a therapeutically effective amount of norketotifen, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof. Also included are methods of intra-articular injection of norketotifen, such as into a joint of a subject in need thereof.

## Claims

### Claim 1

A method of treating a TNFα associated arthritic disorder in a subject in need of such treatment, the method comprising orally or topically administering to the subject in need thereof a therapeutically effective amount of norketotifen, an isomer, an isomeric mixture, a prodrug, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a human subject, a dog, or a horse.

### Claim 3 (depends on 1)

The method of claim 1, wherein the arthritic disorder is rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis, psoriatic arthritis, or ankylosing spondylitis.

### Claim 4 (depends on 1)

The method of claim 1, further comprising co-administering with norketotifen a monoclonal antibody or protein that specifically binds TNFα, IL-5, IL-4 and/or IL-13.

### Claim 5 (depends on 1)

The method of claim 1, further comprising co-administering methotrexate with the norketotifen.

### Claim 6 (depends on 1)

The method of claim 1, further comprising co-administering a corticosteroid with the norketotifen.

### Claim 7 (depends on 1)

The method of claim 1, wherein the norketotifen is orally administered in the form of a tablet, a capsule, or a syrup.

### Claim 8 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of norketotifen is from about 1 mg to about 30 mg of racemic norketotifen, an isomer, a prodrug or a pharmaceutically acceptable salt thereof, calculated as norketotifen free base and administered one or more times daily.

### Claim 9

A method of treating a TNFα associated arthritic disorder in a subject in need of such treatment, the method comprising intra-articularly injecting to the subject in need thereof a therapeutically effective amount of norketotifen, an isomer, an isomeric mixture, or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the subject is an osteoarthritis patient with a demonstrated resistance to orally administered norketotifen.

### Claim 11 (depends on 9)

The method of claim 9, wherein injecting is performed into a joint of the subject.

### Claim 12 (depends on 9)

The method of claim 9, wherein the subject is a human, a dog or a horse.
